Skip to content

Rolapitant

    Brands

    DEA Class; Rx

    Common Brand Names; Varubi

    • Antiemetic Agents; 
    • NK1 Receptor Antagonists

    Substance P/neurokinin 1 (NK1) receptor antagonist
    Used in combination with dexamethasone and a 5-HT3 receptor antagonist for the prevention of CINV
    Contraindicated with CYP2D6 substrates with a narrow therapeutic index, such as thioridazine and pimozide

    Indicated for delayed chemotherapy-induced nausea/vomiting prophylaxis, in combination with other antiemetic agents.

    Coadministration with CYP2D6 substrates with a narrow therapeutic index (eg, thioridazine and pimozide)

    Hypersensitivity to any component of the product

    <2 years of age

    Tablets

    • HEC

      • Neutropenia (9%)

      • Hiccups (5%)

      • Abdominal pain (3%)

    • MEC

      • Decreased appetite (9%)

      • Neutropenia (7%)

      • Dizziness (6%)

      • Dyspepsia (4%)

      • Urinary tract infection (4%)

      • Stomatitis (4%)

      • Anemia (3%)

    —

    Limited data in pregnant women are insufficient to inform a drug associated risk of adverse developmental outcome

    Unknown if distributed in human breast milk and no data on effects on breastfed infant or on milk production

    Adults

    180 mg orally or 166.5 mg intravenously as a single dose on day 1 of the chemotherapy regimen.

    Geriatric

    180 mg orally or 166.5 mg intravenously as a single dose on day 1 of the chemotherapy regimen.

    Adolescents

    Safety and efficacy have not been established.

    Children

    Safety and efficacy have not been established.

    Rolapitant

    tablet

    • 90mg